2016
DOI: 10.7314/apjcp.2016.17.4.1817
|View full text |Cite
|
Sign up to set email alerts
|

Ginsenoside-Rh2 Inhibits Proliferation and Induces Apoptosis of Human Gastric Cancer SGC-7901 Side Population Cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
16
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(19 citation statements)
references
References 13 publications
(13 reference statements)
3
16
0
Order By: Relevance
“…We found that the inhibitory effects of GRh2 on PC growth mainly stemmed from the suppression of cell proliferation, rather than from the activation of cell apoptosis. This finding is consistent with most previous reports, as an anti‐proliferative role of GRh2 has been demonstrated in several cancers …”
Section: Discussionsupporting
confidence: 94%
“…We found that the inhibitory effects of GRh2 on PC growth mainly stemmed from the suppression of cell proliferation, rather than from the activation of cell apoptosis. This finding is consistent with most previous reports, as an anti‐proliferative role of GRh2 has been demonstrated in several cancers …”
Section: Discussionsupporting
confidence: 94%
“…The results revealed that GRh2 impaired HeLa cell proliferation in a doseand time-dependent manner. These findings are in accordance with previous reports that demonstrated that ginseng Rh2 prevents cell proliferation in colon, lung, liver, and gastric cancers, in addition to leukemia and glioblastoma (38)(39)(40)(41)(42). In addition, it was observed that GRh2 inhibited the activation of the Akt pathway in HeLa cells.…”
Section: Discussionsupporting
confidence: 94%
“…The ginsenoside Rh 2 could suppress proliferation in several cancer cells, including human breast cancer (MCF-7) [77], lung cancer adenocarcinoma (A549 cells) [78], human colorectal carcinoma (HCT116) [79], prostate cancer (LNCaP and PC3) [56]. Leukemia (HL-60) [80], uterine leiomyoma [81], neuroblastoma (SK-N-BE-2) [82], glioblastoma multiforme (GBM) [83], human gastric cancer (SGC-7901) [84], hepatocellular carcinoma (HPEG-2) [85], intestinal (Int-407 and Caco-2) [86] and mouse melanoma (B16) [87].…”
Section: Pharmacological Studiesmentioning
confidence: 99%